Histamine Pharmacogenetics in Children With Atopic Dermatitis
Atopic dermatitis (AD) is a common condition in the pediatric population, affecting an
estimated 15% of all children greater than 18 months of age in the United States. It is now
recognized that AD is a disease of significant heterogeneity with respect to both disease
severity and response to conventional pharmacologic therapies. With the recognition of this
variability comes the understanding that, as with many other allergic disease, there exist
many specific disease phenotypes that ultimately govern response to pharmacologic
intervention. The characterization of these unique phenotypes and their associated biologic
mediators is therefore of critical therapeutic importance in the development of disease and
patient-specific treatment strategies.
The long term objective of this research is to explore the effects of genetic, environmental
and developmental influences on the primary determinants of histamine action in atopic
children and to identify potential histamine "haplotypes" that may be predictive of disease
severity, progression and/or response to therapy.
The primary hypothesis is the presence of HNMT T314 allele and /or slow acetylation genotype
is associated with childhood atopic dermatitis.
Observational Model: Case Control, Time Perspective: Retrospective
Mary Jayne Kennedy, Pharm D.
Virginia Commonwealth University
United States: Federal Government
|Children's National Medical Center||Washington, District of Columbia 20010-2970|
|Children's Mercy Hospital||Kansas City, Missouri 64108|
|Arkansas Children's Hospital||Little Rock, Arkansas 72202-3591|
|University of California at San Diego||La Jolla, California 92093|
|Kosair Charities Pediatric Clinical Research Unit||Louisville, Kentucky 40202|
|Wayne State University/Children's Hospital of Michigan||Detroit, Michigan 48201|
|Baylor College of Medicine/Texas Children's Cancer Center||Houston, Texas 77030|